Q4 2020 13F Holders as of 31 Dec 2020
-
Type / Class
-
Equity / Common Stock, $0.0001 par value per share
-
Shares outstanding
-
30,284,111
-
Total 13F shares
-
15,819,144
-
Share change
-
+4,241,426
-
Total reported value
-
$1,114,418,058
-
Price per share
-
$70.54
-
Number of holders
-
78
-
Value change
-
+$300,498,502
-
Number of buys
-
66
-
Number of sells
-
9
Institutional Holders of Keros Therapeutics, Inc. - Common Stock, $0.0001 par value per share (KROS) as of Q4 2020
As of 31 Dec 2020,
Keros Therapeutics, Inc. - Common Stock, $0.0001 par value per share (KROS) was held by
78 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
15,819,144 shares.
The largest 10 holders included
FMR LLC, RA CAPITAL MANAGEMENT, L.P., ORBIMED ADVISORS LLC, Foresite Capital Management IV, LLC, BlackRock Inc., VR Adviser, LLC, VANGUARD GROUP INC, Consonance Capital Management LP, Nantahala Capital Management, LLC, and ALKEON CAPITAL MANAGEMENT LLC.
This page lists
79
institutional shareholders reporting positions in this security
for the Q4 2020 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.